Importantly,METTL3 mRNA and protein are expressed at higher levels in AML cellsthan in healthy HSPCs, which can result in a therapeutic window totarget the protein with inhibitors and degraders. This evidence concerns the gene METTL3 and acute myeloid leukemia.